PRISM BioLab Co

PRISM BioLab Co Market Cap per Employee

The Market Cap per Employee of PRISM BioLab Co (206A.T) as of Oct 23, 2026 is 430.17 M JPY. In the previous year, Market Cap per Employee was 430.17 M JPY — a change of 0.00% (lower).

Market Cap per Employee

430.17 MJPY

YoY

0.00%

Last updated:

Market Cap per Employee of PRISM BioLab Co is 2025 430.17 M JPY. Market Cap per Employee of PRISM BioLab Co was 2024 430.17 M JPY. It decreases by 0.00% lower compared to the previous year.

The PRISM BioLab Co Market Cap per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market Cap per Employee
Date
Market Cap per Employee
Jan 1, 2022
430.17 M JPY
Jan 1, 2023
430.17 M JPY
Jan 1, 2024
430.17 M JPY
Jan 1, 2025
430.17 M JPY
The PRISM BioLab Co Market Cap per Employee history
YEARMarket Cap per EmployeeYoY
430.17 MJPY0.00%
430.17 MJPY0.00%
430.17 MJPY0.00%
430.17 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PRISM BioLab Co Stock analysis

What does PRISM BioLab Co do? PRISM BioLab Co Ltd generates revenue through two distinct business models in the pharmaceuticals sector. The in-house development business focuses on selecting drug discovery targets and creating programs internally using their PepMetics technology platform. The joint development business collaborates with pharmaceutical companies to develop drug discovery programs leveraging their proprietary PepMetics technology. Both models utilize the company's owned drug discovery platform to create new pharmaceutical products. The company's primary clients are pharmaceutical companies seeking to develop new drugs through partnerships with PRISM BioLab's technology. PRISM BioLab's business model centers on its PepMetics technology, which serves as the foundation for both its in-house development and joint development segments. The company builds new drug discovery platforms and develops new drugs through these segments, targeting pharmaceutical companies as their main customers. The firm's research and development activities are conducted using their owned technology, which differentiates their approach in the drug discovery market. The company's revenue streams are derived from pharmaceutical companies that partner with PRISM BioLab for drug discovery programs. By utilizing their PepMetics technology platform, the company creates targeted drug discovery solutions that are developed either internally or in collaboration with pharmaceutical partners. This approach allows PRISM BioLab to generate income through both direct development efforts and collaborative projects with industry clients. PRISM BioLab Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PRISM BioLab Co stock

Market Cap per Employee of PRISM BioLab Co is 430.17 M JPY in 2025.

Market Cap per Employee of PRISM BioLab Co changed from 430.17 M JPY to 430.17 M JPY, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Market Cap per Employee PRISM BioLab Co since 2006 – with annual values, charts, and detailed analysis.

Market cap per employee shows the market value attributed to each employee. Technology companies typically have higher values due to intellectual capital.

Market Cap per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Market Cap per Employee's PRISM BioLab Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — PRISM BioLab Co

All Key Metrics — PRISM BioLab Co